XASX
EMD
Market cap16mUSD
Oct 09, Last price
0.04AUD
1D
2.44%
1Q
10.53%
IPO
-67.69%
Name
Emyria Ltd
Chart & performance
P/E
—
P/S
6.20
EPS
—
Div yield, %
—
Shrs. gr., 5y
27.43%
Rev. gr., 5y
14.45%
Revenues
4m
+178.16%
Net income
-6m
L+94.56%
CFO
-5m
L+68.52%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Emyria Limited is a biotechnology firm currently in the clinical stage, dedicated to creating therapies for medical conditions that lack effective treatments. The company's work primarily involves the development of cannabinoid-derived pharmaceuticals, alongside an initiative for discovering new MDMA-based drugs. Among its pipeline, EMD-RX5 is being explored for psychological distress and irritable bowel syndrome, while EMD-RX7 targets a variety of medical conditions. Established in 2018 and based in Leederville, Australia, the company adopted its current name, Emyria Limited, in September 2020, having previously operated as Emerald Clinics Limited.
Key people
Greg Hutchinson
Independent Non-Executive Chairman of the Board · since 2023
Michael Winlo
Managing Director · since 2019
Susan Park
Company Secretary · since 2023
Mohit Kaushal
Non-Executive Director · since 2023
Karen Smith
Non-Executive Director · since 2023
Sir John Tooke
Non-Executive Director · since 2020
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2026‑06 | 2025‑06 | 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||